MEDIGEN VACCINE BIOLOGICS CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.3 TWD | +2.36% |
|
+8.69% | -19.69% |
| 06-13 | Medigen Vaccine Biologics Corporation Announces General Manager | CI |
| 06-13 | Medigen Vaccine Biologics Corporation Announces Audit Committee and Remuneration Committee Member Changes | CI |
ETFs positioned on Medigen Vaccine Biologics Corporation
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 2 M€ | -.--% | ||
| 0.01% | 114 M€ | +5.88% | - | |
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 7 M€ | +3.59% | - | |
| 0.00% | 32 M€ | +4.18% | - |
Medigen Vaccine Biologics Corp is a Taiwan-based company principally engaged in the development and manufacture of vaccines and biological agents. The Company is engaged in the research, design, development, manufacture, and sale of cell culture vaccines such as influenza vaccines, enterovirus vaccines and dengue vaccines, as well as other biological agents. The main products include enterovirus 71 vaccines (Envacgen), quadrivalent seasonal influenza vaccines, and coronavirus disease 2019 (COVID-19) vaccines. The Company primarily distributes products in Taiwan.
Sector
Pharmaceuticals
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.69% | 556M | |
| +1.93% | 95.18B | |
| -0.13% | 37.55B | |
| -10.43% | 33.75B | |
| +77.76% | 28.2B | |
| -14.82% | 15.63B | |
| -3.06% | 13.63B | |
| -12.76% | 11.5B | |
| +181.73% | 10.81B | |
| -53.92% | 9.23B |
- Stock Market
- Equities
- 6547 Stock
- Funds and ETFs Medigen Vaccine Biologics Corporation
